Form 4: Third Rock Ventures Sells TNGX Shares

Third Rock Ventures IV, L.P., a 10% owner and director, sold 477,401 shares of Tango Therapeutics, Inc. common stock for approximately $4.84 million.

Summary

• Third Rock Ventures IV, L.P., a 10% owner and director of Tango Therapeutics, Inc. (TNGX), disposed of 477,401 shares of common stock.
• The transaction occurred on October 23, 2025, at a weighted average price of $10.152 per share.
• The shares were sold in multiple transactions with prices ranging from $10.00 to $10.65.
• Following this transaction, Third Rock Ventures IV, L.P. directly holds 13,386,574 shares of Tango Therapeutics, Inc.
• The sale was executed pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to a significant insider sale by a 10% owner and director, even though it was pre-planned. While not indicative of operational issues, it can impact investor confidence.

Positives

• The sale was conducted under a Rule 10b5-1(c) plan, indicating a pre-arranged transaction rather than an immediate reaction to new, undisclosed information.

Negatives

• A significant sale of 477,401 shares by a 10% owner and director could be perceived negatively by the market, potentially signaling a reduction in conviction or a need for liquidity.
• The total value of shares sold is approximately $4.84 million, representing a notable divestment.

Risks

• No specific risks related to the issuer's operations or financial health are mentioned. The primary risk implied is the potential negative market perception of an insider sale.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding Tango Therapeutics, Inc.'s future performance or strategic direction.

Industry Context

Insider sales, particularly by large institutional investors or directors, are closely watched in the biotechnology sector as they can sometimes signal shifts in investor confidence or portfolio rebalancing. While this sale is under a 10b5-1 plan, the sheer volume could still draw attention, especially in a sector sensitive to funding and investor sentiment.

Comparison to Industry Standards

• This Form 4 filing does not provide sufficient information to compare Tango Therapeutics' operational or financial results against global industry benchmarks or specific comparable companies/projects. It solely reports an insider trading transaction.

Related Party Transactions

• The sale of 477,401 shares of common stock by Third Rock Ventures IV, L.P., which is a 10% owner and has a director relationship with Tango Therapeutics, Inc., constitutes a related party transaction.

Stakeholder Impact

• Shareholders: May interpret the insider sale as a negative signal, potentially leading to downward pressure on the stock price.
• Management: Could face questions regarding the implications of a major investor reducing their stake.
• Employees: No direct impact mentioned, but a significant stock movement could affect morale or stock-based compensation value.

Next Steps

• This filing does not mention any specific future actions, events, or milestones for Tango Therapeutics, Inc.

Key Dates

Recommendation

While a significant insider sale by a 10% owner and director is generally a negative signal, the transaction was executed under a Rule 10b5-1 plan, suggesting it was pre-scheduled and not necessarily a reaction to new, adverse information. Without additional context on the company's fundamentals or other market catalysts, a 'hold' recommendation is appropriate. Investors should monitor future filings and company performance for further insights rather than reacting solely to this single insider transaction.

Keywords

Tango Therapeutics, TNGX, Third Rock Ventures, Insider Sale, Form 4, Equity Transaction, 10b5-1 Plan, Biotechnology, Venture Capital